top of page


In 2023, Corporis Medical completed a Series B, all equity financing round, including the conversion of existing convertible loans. The round was led by Unorthodox Ventures, a venture capital firm based in Austin, Texas, with participation from existing investors including Brightlands Venture Partners and LIOF.
Proceeds will be used to fund a Randomized Controlled Trial for Mediclose™, as well as clinical validation of the fully integrated Laprixa™ System. 
We are pleased that Unorthodox Ventures and our current stakeholders have shown unwavering confidence in our products that improve outcomes of surgical interventions. This round of funding will allow us to take important steps necessary to enable a market launch.

bottom of page